Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cancer worldwide
3.2.1.2 Technological advancements in drug development
3.2.1.3 Growing geriatric population
3.2.1.4 Rising adoption of combination therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High development costs of drugs
3.2.2.2 Adverse effects and toxicity
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
3.8 Reimbursement scenario
3.9 Future market trends
3.10 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Branded drugs
5.3 Generic drugs
Chapter 6 Market Estimates and Forecast, By Drug Class, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Antimetabolites
6.3 Antitumor antibiotics
6.4 Plant alkaloids
6.5 Alkylating agents
6.6 Other drug classes
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Oncology
8.3 Rheumatoid arthritis
8.4 Multiple sclerosis
8.5 Other applications
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Amgen Inc.
11.2 Bristol-Myers Squibb Company
11.3 Eli Lilly and Company
11.4 F. Hoffmann-La Roche Ltd.
11.5 Fresenius Kabi AG
11.6 Merck & Co., Inc.
11.7 Novartis AG
11.8 Pfizer, Inc.
11.9 Sanofi
11.10 Teva Pharmaceutical Industries Ltd.
